Finance

Lists
Why is 4547 down 3,39%?
Dive Deeper
4547:TYO
Kissei Pharmaceutical Co Ltd
3 700,00 JP¥
-3,39%
(-130,00) 1D
2-окт., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4547...
Open
3 810 JP¥
High
3 815 JP¥
Low
3 690 JP¥
Mkt. cap
172,21 млд
Avg. vol.
66,55 миң
Volume
97,50 миң
Dividend
3,24%
Quarterly dividend
30 JP¥
Ex-dividend date
2026-ж., 29-сен.
P/E ratio
10,97
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 млн
No. of employees
2 миң
Open
3 810 JP¥
High
3 815 JP¥
Low
3 690 JP¥
Mkt. cap
172,21 млд
Avg. vol.
66,55 миң
Volume
97,50 миң
Dividend
3,24%
Quarterly dividend
30 JP¥
Ex-dividend date
2026-ж., 29-сен.
P/E ratio
10,97
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 млн
No. of employees
2 миң
News stories
From web sources and news partners
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include: Difelikefalin Fostamatinib Linzagolix Mitiglinide Remogliflozin etabonate Silodosin Tranilast In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1,79 миң
Founded1946-ж., 9-авг.
HeadquartersMatsumoto, Nagano, Япония
SectorPharmaceutical industry
Last report
2026-ж., 31-июл.
Fiscal period
Q1 2027
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
23,39 млд / 22,42 млд
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
23,64 млд
26,80 млд
24,77 млд
23,39 млд
Cost of goods sold
12,03 млд
14,50 млд
13,95 млд
11,96 млд
Cost of revenue
12,03 млд
14,50 млд
13,95 млд
11,96 млд
Research and development expenses
-
-
22,52 млд
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
20,55 млд
9,15 млд
-15,41 млд
10,34 млд
Operating expense
20,55 млд
9,15 млд
10,07 млд
10,34 млд
Total operating expenses
32,59 млд
23,65 млд
24,02 млд
22,29 млд
Operating income
-8,95 млд
3,16 млд
756,00 млн
1,10 млд
Other non operating income
1,00 млн
10,00 млн
-10,00 млн
10,00 млн
EBT including unusual items
3,66 млд
4,20 млд
3,28 млд
6,29 млд
EBT excluding unusual items
-8,82 млд
3,52 млд
948,00 млн
1,82 млд
Income tax expense
305,00 млн
915,00 млн
482,00 млн
1,53 млд
Effective tax rate
8,33%
21,81%
14,68%
24,32%
Other operating expenses
-
-
129,00 млн
-
Net income
3,26 млд
3,23 млд
2,76 млд
4,72 млд
Net profit margin
13,81%
12,05%
11,16%
20,19%
Earnings per share
-
-
-
-
Interest and investment income
212,00 млн
614,00 млн
224,00 млн
729,00 млн
Interest expense
-7,00 млн
-7,00 млн
-8,00 млн
-8,00 млн
Net interest expenses
205,00 млн
607,00 млн
216,00 млн
721,00 млн
Depreciation and amortization charges
-
-
2,83 млд
-
EBITDA
-7,82 млд
4,31 млд
1,92 млд
2,26 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору